Rize Oncology Inc.
RIZE
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.40% | -3.85% | -43.27% | -50.77% | -53.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.17% | -5.13% | -42.64% | -52.15% | -56.49% |
| Operating Income | 21.17% | 5.13% | 42.64% | 52.15% | 56.49% |
| Income Before Tax | 19.96% | 7.03% | 46.97% | 56.37% | 59.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.96% | 7.03% | 46.97% | 56.37% | 59.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.96% | 7.03% | 46.97% | 56.37% | 59.87% |
| EBIT | 21.17% | 5.13% | 42.64% | 52.15% | 56.49% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 10.13% | 16.36% | 47.95% | 57.14% | 63.93% |
| Normalized Basic EPS | 10.20% | 16.54% | 48.07% | 57.21% | 64.10% |
| EPS Diluted | 10.13% | 16.36% | 47.95% | 57.14% | 63.93% |
| Normalized Diluted EPS | 10.20% | 16.54% | 48.07% | 57.21% | 64.10% |
| Average Basic Shares Outstanding | -16.24% | -10.36% | -4.08% | 1.66% | 13.52% |
| Average Diluted Shares Outstanding | -16.24% | -10.36% | -4.08% | 1.66% | 13.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |